Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 1/20 | 0.51 |
| ▸ | PPARA | Q07869 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.50 |
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | CA2 | P00918 | 2/20 | 0.48 |
| ▸ | NAMPT | P43490 | 2/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | MMP1 | P03956 | 1/20 | 0.47 |
| ▸ | MMP2 | P08253 | 1/20 | 0.47 |
| ▸ | MMP9 | P14780 | 1/20 | 0.47 |
| ▸ | MMP8 | P22894 | 1/20 | 0.47 |
| ▸ | MMP13 | P45452 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.47 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18664385 | 0.96 | HDAC1 (0.49) | PPARGPPARAL3MBTL1GAACA2 | |
| SCHEMBL27262445 | 0.96 | PPARG (0.48) | PPARGPPARAL3MBTL1GAACA2 | |
| Methyl Alcohol SCHEMBL12492352 | 0.92 | PPARG (0.46) | PPARGPPARAL3MBTL1GAACA2 | |
| SCHEMBL29510988 | 0.92 | PPARD (0.48) | PPARGPPARAL3MBTL1GAACA2 | |
| SCHEMBL13456452 | 0.91 | CA2 (0.49) | PPARGPPARAL3MBTL1GAACA2 | |
| SCHEMBL26185842 | 0.90 | MAOB (0.58) | GAACA2CA1CYP2C9CYP2C19 | |
| SCHEMBL29460423 | 0.87 | MMP1 (0.51) | L3MBTL1GAANAMPTCYP2C9CYP2C19 | |
| SCHEMBL1717941 | 0.86 | MAPT (0.56) | PPARGPPARACA2NAMPTCA1 | |
| SCHEMBL3558360 | 0.86 | PPARG (0.49) | PPARGPPARAGAAMMP1MMP2 | |
| SCHEMBL3180689 | 0.86 | L3MBTL1 (0.61) | L3MBTL1GAACA2NAMPTCA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 233 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250214963-A1 | SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | PFIZER INC. | 2025-07-03 | — | — | US | disclosed |
| US-20240109862-A1 | SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | PFIZER INC. | 2024-04-04 | — | — | US | disclosed |
| US-20220251066-A1 | SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | PFIZER INC. | 2022-08-11 | — | — | US | disclosed |
| CN-109153648-B | Benzazepine dicarboxamide compounds having tertiary amide functional group | 豪夫迈·罗氏有限公司 | 2022-07-22 | — | — | CN | disclosed |
| EP-3329918-B1 | C-MET MODULATORS AND METHODS OF USE | EXELIXIS INC (US) | 2022-05-25 | — | — | EP | disclosed |
| US-11124482-B2 | C-met modulators and methods of use | EXELIXIS, INC. (US) | 2021-09-21 | — | — | US | disclosed |
| US-20210253530-A9 | C-MET MODULATORS AND METHODS OF USE | EXELIXIS, INC. | 2021-08-19 | — | — | US | disclosed |
| CN-106349233-B | 3, 4-diphenyl-4H-1, 2, 4-triazole derivative and preparation method and application thereof | 上海翰森生物医药科技有限公司 | 2021-06-01 | — | — | CN | disclosed |
| US-20200331860-A1 | C-Met Modulators and Methods of Use | EXELIXIS INC (US) | 2020-10-22 | — | — | US | disclosed |
| EP-3464245-B1 | BENZAZEPINE DICARBOXAMIDE COMPOUNDS WITH TERTIARY AMIDE FUNCTION | HOFFMANN LA ROCHE (CH) | 2020-10-14 | — | — | EP | disclosed |
| US-5693636-A | Bicyclic fibrinogen antagonists | SMITHKLINE BEECHAM CORPORATION (US) | 1997-12-02 | — | — | US | disclosed |
| EP-0799191-A1 | ACETAMIDINE DERIVATIVES AND THEIR USE AS INHIBITORS FOR THE NITRIC OXIDE SYNTHASE | THE WELLCOME FOUNDATION LIMITED (GB) | 1997-10-08 | — | — | EP | disclosed |
| US-5563141-A | INHIBIT CELL ADHESION FOR EXAMPLE, PLATELET AGGRE GATION | ZENECA LIMITED (GB) | 1996-10-08 | — | — | US | disclosed |
| WO-1996019440-A1 | ACETAMIDINE DERIVATIVES AND THEIR USE AS INHIBITORS FOR THE NITRIC OXIDE SYNTHASE | THE WELLCOME FOUNDATION LIMITED (GB) | 1996-06-27 | — | — | WO | disclosed |
| WO-1996002510-A1 | NOVEL 1-[4(AMINO METHYL)PHENYL] SUBSTITUTED QUINOLONE CARBOXYLIC ACIDS | BAYER AKTIENGESELLSCHAFT (DE) | 1996-02-01 | — | — | WO | disclosed |
| WO-1996002511-A1 | NOVEL N1 DIVERSE 6-FLUORINE-8-DIFLUOROMETHOXY SUBSTITUTED QUINOLONE CARBOXYLIC ACIDS | BAYER AKTIENGESELLSCHAFT (DE) | 1996-02-01 | — | — | WO | disclosed |
| EP-0690847-A1 | HETEROCYCLIC COMPOUNDS AS PLATELET AGGREGATION INHIBITORS | ZENECA LIMITED (GB) | 1996-01-10 | — | — | EP | disclosed |
| WO-1994022835-A2 | HETEROCYCLIC COMPOUNDS AS PLATELET AGGREGATION INHIBITORS | ZENECA LIMITED (GB) | 1994-10-13 | — | — | WO | disclosed |
| US-4548904-A | FORMING REACTION PRODUCT OF PROTEIN AND REAGENT, DEGRADATION TO REMOVE TERMINAL AMINO ACID, THEN CHROMATOGRAPHY ANALYSIS | MOLECULAR GENETICS RESEARCH & DEVELOPMENT (US) | 1985-10-22 | — | — | US | disclosed |
| EP-0113538-A2 | Protein sequencing method and reagent | MOLECULAR GENETICS RESEARCH & DEVELOPMENT LIMITED PARTNERSHIP (US) | 1984-07-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200331860-A1 | C-Met Modulators and Methods of Use | FLT4, FLT1, MET | PPARG 2948/4885PPARA 3721/4885L3MBTL1 2294/4885 |
| US-20250214963-A1 | SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | GPR119, INSR, LYAR | PPARG 726/4885PPARA 641/4885L3MBTL1 616/4885 |
| US-20210253530-A9 | C-MET MODULATORS AND METHODS OF USE | FLT4, FLT1, MET | PPARG 2948/4885PPARA 3721/4885L3MBTL1 2294/4885 |
| US-20240109862-A1 | SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | GPR119, INSR, LYAR | PPARG 726/4885PPARA 641/4885L3MBTL1 616/4885 |
| US-11124482-B2 | C-met modulators and methods of use | FLT4, FLT1, MET | PPARG 2948/4885PPARA 3721/4885L3MBTL1 2294/4885 |
| US-20220251066-A1 | SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | GPR119, INSR, LYAR | PPARG 726/4885PPARA 641/4885L3MBTL1 616/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.